FI106801B - Förfarande för framställning av terapeutiskt användbara gallsyraderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara gallsyraderivat Download PDF

Info

Publication number
FI106801B
FI106801B FI932659A FI932659A FI106801B FI 106801 B FI106801 B FI 106801B FI 932659 A FI932659 A FI 932659A FI 932659 A FI932659 A FI 932659A FI 106801 B FI106801 B FI 106801B
Authority
FI
Finland
Prior art keywords
eller
med
alkyl
radical
group
Prior art date
Application number
FI932659A
Other languages
English (en)
Finnish (fi)
Other versions
FI932659A0 (fi
FI932659A (fi
Inventor
Guenther Wess
Werner Kramer
Heiner Glombik
Alfons Enhsen
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI932659A0 publication Critical patent/FI932659A0/fi
Publication of FI932659A publication Critical patent/FI932659A/fi
Application granted granted Critical
Publication of FI106801B publication Critical patent/FI106801B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Train Traffic Observation, Control, And Security (AREA)
  • Motorcycle And Bicycle Frame (AREA)
  • Saccharide Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
FI932659A 1992-06-12 1993-06-10 Förfarande för framställning av terapeutiskt användbara gallsyraderivat FI106801B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4219274 1992-06-12
DE4219274 1992-06-12

Publications (3)

Publication Number Publication Date
FI932659A0 FI932659A0 (fi) 1993-06-10
FI932659A FI932659A (fi) 1993-12-13
FI106801B true FI106801B (sv) 2001-04-12

Family

ID=6460884

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932659A FI106801B (sv) 1992-06-12 1993-06-10 Förfarande för framställning av terapeutiskt användbara gallsyraderivat

Country Status (21)

Country Link
US (1) US5428182A (sv)
EP (1) EP0573848B1 (sv)
JP (1) JP3403218B2 (sv)
KR (1) KR100319562B1 (sv)
AT (1) ATE160783T1 (sv)
AU (1) AU663592B2 (sv)
CA (1) CA2098256C (sv)
CY (1) CY2117B1 (sv)
CZ (1) CZ285104B6 (sv)
DE (1) DE59307759D1 (sv)
DK (1) DK0573848T3 (sv)
ES (1) ES2111092T3 (sv)
FI (1) FI106801B (sv)
GR (1) GR3025799T3 (sv)
HU (1) HU216636B (sv)
IL (1) IL105980A (sv)
NO (1) NO304653B1 (sv)
NZ (1) NZ247827A (sv)
SK (1) SK280819B6 (sv)
TW (1) TW228004B (sv)
ZA (1) ZA934150B (sv)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840879A (en) * 1996-12-06 1998-11-24 Wang; Edge R. Reagents and solid supports for improved synthesis and labeling of polynucleotides
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7674778B2 (en) 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
ES2318922B1 (es) * 2005-05-30 2010-02-12 Universidade De Santiago De Compostela Nuevos dimeros derivados de acidos biliares funcionalizados en la posicion 3 del anillo a. metodo para la sintesis y aplicaciones.
KR100800312B1 (ko) * 2006-01-25 2008-02-04 (주)테크윙 테스트핸들러 및 테스트핸들러의 로딩방법
CN101078006B (zh) 2006-05-26 2012-06-06 上海凯信生物科技有限公司 一株高产四甲基吡嗪的短小芽孢杆菌
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
RS60901B1 (sr) 2010-11-08 2020-11-30 Albireo Ab Ibat inhibitori za lečenje oboljenja jetre
MX345040B (es) 2010-11-08 2017-01-16 Albireo Ab Una combinacion farmaceutica que comprende un inhibidor de ibat y un aglutinante de acido biliar.
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3100691A1 (en) 2018-06-20 2019-12-26 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
FI3921028T3 (sv) 2019-02-06 2023-01-31 Bensotiadiazepinföreningar och användning av dem som gallsyramodulatorer
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2022520121A (ja) 2019-02-12 2022-03-28 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞を治療する方法
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023504645A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US20240207286A1 (en) 2022-12-09 2024-06-27 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2931817A (en) * 1956-05-31 1960-04-05 Monsanto Chemicals Steroid sulfite ester polymers
DE1768345B2 (de) * 1968-05-03 1976-12-02 Hoechst Ag, 6000 Frankfurt Dimere steroid-21-alkylcarbonate und verfahren zu ihrer herstellung
US3916002A (en) * 1973-12-17 1975-10-28 Taubert Hans Dieter Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same
NL7415669A (nl) * 1974-12-02 1976-06-04 Akzo Nv Werkwijze ter bereiding van een nieuwe ester van 19-nor-testosteron.
FI106800B (sv) * 1990-12-06 2001-04-12 Hoechst Ag Förfarande för framställning av nya terapeutiskt användbara dimeriska gallsyraderivat
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
TW289021B (sv) * 1993-05-08 1996-10-21 Hoechst Ag

Also Published As

Publication number Publication date
JP3403218B2 (ja) 2003-05-06
CZ113493A3 (en) 1994-01-19
ZA934150B (en) 1994-01-13
TW228004B (sv) 1994-08-11
EP0573848A3 (de) 1995-06-07
EP0573848A2 (de) 1993-12-15
FI932659A0 (fi) 1993-06-10
KR100319562B1 (ko) 2002-05-13
IL105980A0 (en) 1993-10-20
AU663592B2 (en) 1995-10-12
DE59307759D1 (de) 1998-01-15
ES2111092T3 (es) 1998-03-01
NO932159D0 (no) 1993-06-11
AU4018093A (en) 1993-12-16
US5428182A (en) 1995-06-27
SK280819B6 (sk) 2000-08-14
SK58593A3 (en) 1994-03-09
CZ285104B6 (cs) 1999-05-12
HU9301716D0 (en) 1993-09-28
GR3025799T3 (en) 1998-03-31
KR940005652A (ko) 1994-03-22
NO932159L (no) 1993-12-13
HUT64772A (en) 1994-02-28
CA2098256C (en) 2004-08-24
CA2098256A1 (en) 1993-12-13
CY2117B1 (en) 2002-04-26
ATE160783T1 (de) 1997-12-15
IL105980A (en) 1997-11-20
HU216636B (hu) 1999-07-28
NO304653B1 (no) 1999-01-25
JPH0687884A (ja) 1994-03-29
DK0573848T3 (da) 1998-08-10
NZ247827A (en) 1995-08-28
FI932659A (fi) 1993-12-13
EP0573848B1 (de) 1997-12-03

Similar Documents

Publication Publication Date Title
FI106801B (sv) Förfarande för framställning av terapeutiskt användbara gallsyraderivat
AU673419B2 (en) Monomeric bile acid derivatives, processes for their preparation and the use of these compounds as medicaments
KR100333149B1 (ko) 담즙산의테트라졸유도체및이를포함하는약제
CZ281075B6 (cs) Deriváty žlučových kyselin, způsob jejich výroby a jejich použití jako léčiva
US6384024B1 (en) Bile salt conjugates
CZ113494A3 (en) Derivatives of nor-bile acids, process of their preparation and use of said compounds as medicaments
AU766798B2 (en) Pharmaceutical compounds
IE903329A1 (en) Bile acid derivatives, processes for their preparation, and¹use as pharmaceuticals
US4793948A (en) Bile acid derivatives and production thereof
EP0676410B1 (en) Bile acids derivatives useful in the therapy of the biliary calculosis from cholesterol and of the pathologies caused by cholestasis
El Kihel et al. New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines
MXPA06007852A (es) Profarmacos di-esteroidales de estradiol.
AU757366B2 (en) Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism
EP3431478B1 (en) Micromolecular lung-targeting drug
NO310235B1 (no) Pyrimidin-derivater, anvendelse av dem og farmasöytiske blandinger inneholdende dem
EP0208446B1 (en) Fluorescent substance for use as a cell-discriminating agent
US5693770A (en) Process for the manufacture of 3-amino-substituted glycosylated bile acids
EP0444424B1 (en) Bile acid unsaturated derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
JPS6363698A (ja) 胆汁酸誘導体およびその塩ならびにその製造法
MXPA01003207A (en) Propanolamine derivatives linked with bile acid used for treating disorders of the lipid metabolism